

SUPPLEMENTAL MATERIAL

Lathrop et al., <http://www.jem.org/cgi/content/full/jem.20081359/DC1>

A

| Expt. | Phenotype | Spleen | Lymph node | | | | Total |
|--------------|--------------------|--------|------------|-------|-------|-------|--------|
| | | | Mes | Cerv | Axil | Ing | |
| 1 | Foxp3 ⁺ | 322 | 298 | 329 | 285 | 357 | 1,591 |
| | CD44 ^{hi} | 295 | 330 | 246 | 305 | 291 | 1,467 |
| | CD44 ^{lo} | 315 | 306 | 307 | 335 | 274 | 1,537 |
| 2 | Foxp3 ⁺ | 330 | 298 | 301 | 333 | 304 | 1,566 |
| | CD44 ^{hi} | 268 | 321 | 321 | 321 | 298 | 1,529 |
| | CD44 ^{lo} | 333 | 338 | 344 | 344 | 333 | 1,692 |
| 3 | Foxp3 ⁺ | 283 | 361 | 284 | 298 | 280 | 1,506 |
| | CD44 ^{hi} | 283 | 276 | 365 | 311 | 377 | 1,612 |
| | CD44 ^{lo} | 278 | 306 | 278 | 330 | 453 | 1,645 |
| 4 mouse 1 | Foxp3 ⁺ | 146 | 161 | 179 | * | * | 486 |
| | CD44 ^{hi} | 154 | 198 | 139 | * | * | 491 |
| | CD44 ^{lo} | 110 | 123 | 167 | * | * | 400 |
| 4 mouse 2 | Foxp3 ⁺ | 141 | 120 | 164 | * | * | 425 |
| | CD44 ^{hi} | 136 | 143 | 116 | * | * | 395 |
| | CD44 ^{lo} | 113 | 120 | 115 | * | * | 348 |
| 4 mouse 3 | Foxp3 ⁺ | 122 | 153 | 124 | * | * | 399 |
| | CD44 ^{hi} | 161 | 149 | 143 | * | * | 453 |
| | CD44 ^{lo} | 114 | 152 | 115 | * | * | 381 |
| Total: | | 3,870 | 4,124 | 4,003 | 2,959 | 2,967 | 17,923 |




Figure S1. Generation of the peripheral TCR database. (A) Sequence datasets from normal mice. The number of TRAV14 (V α 2) TCR α chain sequences from T cell subsets at each location are shown. Experiment numbers 1–3 consisted of cells pooled from three to five mice, whereas experiment 4 consisted of three independently sequenced mice. Cells from axillary and inguinal LNs were not isolated in experiment 4, as indicated by asterisks. Axil, axillary; Cerv, cervical; Ing, inguinal; Mes, mesenteric. (B) FACS purification strategy. Representative flow cytometric plot of CD4⁺ splenocytes from TClI TCR β transgenic \times *Foxp3^{9ip}* \times *Tcr α ^{+/-}* mice illustrate the three sorted populations: CD44^{hi}, CD44^{lo}, and Foxp3⁺. Numbers indicate percentages in the gates.

| # of times TCR is found | Foxp3 ⁺ | | | | | Foxp3 ⁻ CD44 ^{lo} | | | | | Foxp3 ⁻ CD44 ^{hi} | | | | |
|----------------------------|--------------------|-------|-------|-------|-------|---------------------------------------|-------|-------|-------|-------|---------------------------------------|-------|-------|------|-----|
| | Spl | Mes | Cerv | Axil | Ing | Spl | Mes | Cerv | Axil | Ing | Spl | Mes | Cerv | Axil | Ing |
| 1 | 425 | 494 | 452 | 282 | 246 | 322 | 305 | 315 | 273 | 269 | 347 | 330 | 322 | 218 | 213 |
| 2 | 108 | 121 | 117 | 61 | 55 | 62 | 60 | 56 | 42 | 59 | 78 | 93 | 66 | 46 | 54 |
| 3 | 31 | 46 | 40 | 24 | 18 | 19 | 27 | 21 | 27 | 17 | 39 | 38 | 33 | 21 | 30 |
| 4 | 21 | 22 | 24 | 14 | 15 | 10 | 12 | 14 | 11 | 7 | 18 | 19 | 20 | 17 | 15 |
| 5 | 10 | 10 | 12 | 12 | 7 | 10 | 15 | 14 | 7 | 15 | 16 | 11 | 17 | 7 | 9 |
| 6 | 6 | 9 | 15 | 3 | 7 | 4 | 5 | 4 | 2 | 6 | 5 | 7 | 10 | 7 | 4 |
| 7 | 6 | 4 | 3 | 2 | 5 | 1 | 4 | 8 | 5 | 3 | 6 | 11 | 8 | 1 | 4 |
| 8 | 5 | 5 | 7 | 7 | 4 | 4 | 1 | 2 | 2 | 1 | 4 | 4 | 5 | 3 | 1 |
| 9 | 2 | 1 | 3 | 1 | 5 | 2 | 2 | 4 | 3 | 1 | 3 | 5 | 3 | 4 | 1 |
| 10 | 6 | 2 | 3 | 2 | 4 | 3 | 3 | 1 | 1 | | 3 | 3 | 1 | 1 | 1 |
| 11 | 2 | 1 | | 2 | 1 | 3 | 1 | 3 | | 2 | 7 | 1 | 5 | | 1 |
| 12 | 2 | 1 | 3 | 1 | | 2 | 2 | 1 | 2 | | 2 | | 1 | 1 | 1 |
| 13 | | 3 | 1 | 1 | 2 | 1 | | 1 | 1 | 1 | | 1 | 1 | | 3 |
| 14 | | | 1 | 1 | 2 | 1 | 2 | 2 | | | 2 | | 1 | | |
| 15 | 3 | | | | 2 | 1 | 2 | 1 | 2 | 2 | | 5 | 2 | | 1 |
| 16 | | 2 | | 2 | 1 | 2 | 2 | 3 | 1 | 1 | 1 | 1 | 1 | | |
| 17 | 2 | | | 1 | | 1 | 1 | | | 1 | 1 | 1 | | | |
| 18 | | 1 | | | | 1 | | | 2 | | | 1 | | 1 | |
| 19 | | | 1 | 1 | 1 | 1 | 2 | | 2 | | | 1 | 1 | | |
| 20 | | | | | 1 | | | | 1 | 2 | 1 | | 1 | | |
| 21 | | | | | | 1 | | 1 | 3 | 1 | 1 | | | | |
| 22 | 1 | 1 | | 1 | | 2 | 3 | 1 | | | | | | | |
| 23 | | | | | | 1 | | | | | | | 1 | 2 | 1 |
| 24 | | 1 | 1 | | | 1 | | 1 | | 1 | 1 | | | | |
| 25 | | | 1 | | | | | 1 | | | 1 | | | 1 | |
| 26 | | | 1 | | 1 | 1 | 1 | 1 | | | | | | | |
| 27 | | | | | | | 1 | | | | | | 1 | | |
| 28 | | | | | | | | | | 1 | | 1 | | | |
| 29 | | | | | | 1 | | 1 | 1 | | 1 | | | | |
| 30 | | | | | | | | 1 | | 1 | | 1 | | | |
| 31 | | | | | | | | 1 | 1 | | | | | | |
| 32 | 1 | | | | | | 2 | | | 1 | | | | | |
| 33 | | 1 | | | | | | | 1 | 1 | | | | | |
| 34 | | | | | | | 2 | | | 1 | | | | | |
| 36 | | | | | | | | 1 | | 1 | | | | | |
| 37 | | 1 | | | | 1 | | 1 | | | | | | | |
| 38 | | | 1 | | | | | | | | | | | | |
| 39 | | | | | | | 2 | | | | | | 1 | | 2 |
| 40 | 1 | | | | | | 1 | 1 | | | | | | | |
| 41 | | | | | | 1 | | | | | | | | | |
| 42 | | | | | | 1 | | | | | | | | | |
| 43 | | | | | | | | 1 | | | | 1 | | | |
| 44 | | | | | | | | | | | | | 1 | | |
| 47 | | | | | | | | | | | | | 1 | | |
| 50 | | | | | | | | | | | | 1 | | | |
| 53 | | | | | | 1 | 1 | | | | | 1 | | | |
| 54 | | | | | | | | | | | | | | | 1 |
| 55 | | | | | | | | 1 | | | | | | | |
| 56 | | | | 1 | | | | | | | | | | 1 | |
| 57 | | | | | | | | | | | | 1 | | | |
| 58 | | | | | | 1 | | | | | | | | | |
| 59 | | | | | | | | | 1 | | | | | | |
| 60 | | | | | | | | | | | | | 1 | | |
| 61 | 1 | | | | | | | | | | | | | | |
| 66 | | | | | 1 | | | | | | | | | | |
| 69 | | | | | | | | | | 1 | | | | | |
| 83 | | | | | | | | | | | 1 | | | | |
| 139 | | | | | | | | | | | | | | | 1 |
| 185 | | | | | | | | | | | | | | 1 | |
| Total Unique | 633 | 726 | 686 | 419 | 378 | 460 | 459 | 463 | 391 | 396 | 538 | 538 | 504 | 332 | 343 |
| Total Seq | 1,344 | 1,391 | 1,381 | 916 | 941 | 1,263 | 1,345 | 1,326 | 1,009 | 1,060 | 1,297 | 1,417 | 1,330 | 937 | 966 |
| Est Diversity | 1,791 | 1,934 | 1,766 | 1,163 | 1,032 | 1,546 | 1,290 | 1,388 | 1,237 | 1,095 | 1,362 | 1,256 | 1,231 | 855 | 757 |

Figure S2. Characterization of TRAV14 TCR α datasets from normal mice. The numbers of unique CDR3 amino acid sequences that were found the indicated numbers of times in the pooled TCR α sequence data (Table 1) from the indicated populations are shown. Estimated (Est) diversity is calculated as described in Materials and methods. LNs are shown as in Fig. S1.

| | CDR3 a.a. sequence | location p-value | Foxp3 ⁺ | | | | | Foxp3 ⁻ CD44 ^{lo} | | | | | Foxp3 ⁻ CD44 ^{hi} | | | | | Number of Instances |
|--------------------------------|--------------------|---------------------|--------------------|-----|-----|------|-----|---------------------------------------|-----|-----|------|-----|---------------------------------------|-----|------|------|-----|------------------------|
| | | | Spl | Mes | Crv | Axil | Ing | Spl | Mes | Crv | Axil | Ing | Spl | Mes | Crv | Axil | Ing | |
| Top 15 Foxp3 ⁺ TCRs | AAEPNYNVLY | < 0.01 | 0.6 | 0.1 | 1.9 | 6.1 | 7.0 | | | | | | | | | | | 158 |
| | AARPSGSFNKLT | < 0.01 | 0.3 | 1.7 | 2.8 | 0.2 | | | | | | | | | | | | 69 |
| | AASDGNRRIF | < 0.01 | 4.5 | 0.1 | 0.1 | | 0.1 | | | | | | | | | | | 64 |
| | AARTASLGKQL | < 0.01 | 3.0 | 0.7 | 0.4 | 0.3 | 0.4 | | | | | | | | | | | 63 |
| | AASADYSNNRLLT | 0.92 | 0.7 | 0.4 | 1.8 | 0.8 | 1.6 | | | | | | | 0.3 | | | | 67 |
| | AARNYNQGKLI | 0.84 | 0.7 | 0.9 | 0.6 | 1.9 | 1.5 | 0.2 | 0.1 | 0.5 | 0.4 | 0.5 | 0.2 | 0.1 | 0.1 | 0.4 | | 89 |
| | AASNYQGGRALI | < 0.01 | 0.1 | 0.1 | 0.7 | 2.4 | 2.8 | | | 0.1 | | | | | | | | 61 |
| | AANSPTYQR | 1.00 | 0.9 | 0.9 | 0.9 | 0.9 | 0.5 | | 0.1 | | 0.1 | | 0.2 | | 0.1 | 0.1 | 0.3 | 61 |
| | AASELYQGGRALI | < 0.01 | 0.8 | 2.7 | | 0.1 | 0.1 | | | | | | | 0.1 | | | | 51 |
| | AASDYGSSGNKLI | < 0.01 | 0.6 | 0.2 | 0.6 | 1.7 | 1.6 | | | | 0.2 | | | 0.1 | | | | 53 |
| | AASGTGSWQLI | < 0.01 | 2.4 | 0.6 | 0.1 | | 0.3 | | | | | | | | | | | 45 |
| | AASRGGNYKYV | < 0.01 | 0.2 | 0.1 | 0.6 | 2.1 | 1.1 | | | | | | | | | | | 41 |
| | AASYNTNTGKLT | 0.04 | 0.3 | 0.3 | 0.5 | 0.9 | 1.7 | | | | | | | | | | | 39 |
| | AASSPTYQR | 0.05 | 0.2 | 0.5 | 1.7 | 0.2 | 0.2 | | | 0.1 | 0.1 | | | | 0.1 | | | 41 |
| | AARNNYAQGLT | 1.00 | 0.8 | 1.3 | 0.1 | 0.5 | 0.2 | | | | | | 0.1 | 0.6 | | | | 48 |
| Top 15 CD44 ^{hi} TCRs | AARGVTNSAGNKLT | < 0.01 | | | | 0.4 | | | | | 0.1 | 2.2 | 0.1 | 3.3 | 19.7 | 14.4 | 404 | |
| | AASAVNNYQLI | < 0.01 | | | | | | | | | | 1.1 | 0.2 | 4.5 | 6.0 | 5.6 | 187 | |
| | AARDHNYAQGLT | < 0.01 | 1.3 | 0.2 | 0.1 | 0.4 | 0.2 | | | | | 6.4 | | 0.3 | | 0.5 | 120 | |
| | AAWGYQGGRALI | < 0.01 | 0.1 | | | | | | | 0.1 | | 1.9 | 0.3 | 3.5 | 0.5 | 0.2 | 85 | |
| | AAIPSGNMGYKLT | < 0.01 | | | | | | | | | | 1.9 | 0.3 | 2.9 | 1.0 | 0.6 | 82 | |
| | AASANSPTYQR | 1.00 | 0.5 | 0.4 | 0.4 | 0.9 | 0.1 | 1.9 | 2.4 | 1.1 | 1.3 | 0.7 | 1.2 | 1.3 | 2.0 | 0.6 | 0.6 | 193 |
| | AASDGGSGNKLI | < 0.01 | | 0.1 | | | | | | | | | 0.6 | 4.0 | 0.3 | | 0.1 | 71 |
| | AASAGTGGYKVV | < 0.01 | 0.1 | 0.4 | 0.4 | 0.4 | 0.4 | 0.7 | 0.9 | 0.8 | 0.7 | 0.4 | 0.2 | 0.3 | 1.2 | 2.5 | 2.4 | 133 |
| | AATSSSFSLV | < 0.01 | | | | | | | | | | | 0.2 | | 0.1 | 2.5 | 4.0 | 66 |
| | AASPRLGKQL | < 0.01 | | | | | 0.2 | | | 0.1 | | | 0.2 | | 0.8 | 1.3 | 4.0 | 67 |
| | AAIDLPGTGSNRLT | < 0.01 | | 0.1 | | | | | | | | | 0.5 | 3.7 | | | | 62 |
| | AASMASGSFNKLT | < 0.01 | | 0.1 | | | | | | | | | 0.5 | 3.5 | | | | 57 |
| | AASDTNTGKLT | 1.00 | | | | | | | | | | | 1.3 | 0.5 | 1.7 | 0.2 | 0.3 | 52 |
| | AARPGPEDSNYQLI | < 0.01 | | | | | | | | | | | 0.5 | 3.0 | | | | 49 |
| | AARDPTTGGNNKLT | 1.00 | | | | | | 0.1 | | | | | 0.8 | 0.2 | 1.5 | 1.0 | 0.6 | 50 |
| Top 15 CD44 ^{lo} TCRs | AASATGANTGKLT | < 0.01 | 0.1 | 0.1 | | 0.1 | 0.5 | 4.6 | 3.9 | 4.1 | 5.8 | 6.5 | 0.7 | 0.4 | 0.8 | 0.5 | 0.7 | 294 |
| | AASEDNNNAPR | 1.00 | | 0.1 | 0.1 | 0.3 | 0.1 | 4.2 | 3.0 | 3.0 | 3.1 | 3.0 | | 0.1 | | 0.3 | 0.3 | 196 |
| | AASETGANTGKLT | 0.74 | | 0.2 | 0.1 | | 0.6 | 3.3 | 2.9 | 2.0 | 3.3 | 3.2 | 0.1 | 0.1 | 0.2 | 0.1 | 0.4 | 174 |
| | AASVTGANTGKLT | 0.07 | | | | 0.2 | 0.1 | 1.7 | 2.5 | 2.8 | 2.9 | 3.4 | | 0.2 | | 0.3 | 0.3 | 158 |
| | AASQGGSAKLI | 1.00 | 0.1 | 0.1 | 0.2 | 0.1 | | 3.2 | 2.5 | 3.2 | 1.9 | 1.5 | 0.1 | | 0.2 | 0.3 | 0.1 | 153 |
| | AASGYGSSGNKLI | 1.00 | 0.1 | | 0.1 | 0.4 | 0.6 | 2.3 | 2.9 | 2.3 | 1.9 | 2.3 | | 0.2 | | 0.1 | 0.3 | 142 |
| | AAANTGANTGKLT | 1.00 | | 0.1 | 0.1 | 0.1 | 0.3 | 2.9 | 2.4 | 1.9 | 1.8 | 2.6 | | 0.1 | 0.3 | | 0.5 | 140 |
| | AASRTGANTGKLT | 1.00 | 0.1 | | 0.1 | 0.2 | 1.1 | 1.8 | 2.0 | 2.3 | 2.1 | 3.1 | | 0.1 | 0.3 | 0.1 | | 134 |
| | AASLTGANTGKLT | 1.00 | | 0.1 | 0.1 | | | 2.1 | 1.6 | 1.8 | 2.1 | 2.8 | | 0.1 | | 0.1 | | 123 |
| | AASGGTGGYKVV | 1.00 | | 0.1 | 0.1 | 0.3 | | 1.5 | 1.6 | 2.7 | 2.0 | 1.4 | 0.3 | 0.4 | 0.4 | 0.3 | 1.1 | 112 |
| | AARRNNNNRIF | 1.00 | | | 0.1 | 0.1 | 0.3 | 1.3 | 1.6 | 1.6 | 1.8 | 1.9 | 0.2 | 0.1 | 0.2 | 0.2 | 0.3 | 97 |
| | AARGQGGRALI | 1.00 | | 0.1 | | | 0.1 | 1.3 | 1.0 | 2.2 | 1.5 | 1.9 | | 0.1 | | 0.2 | 0.3 | 95 |
| | AASKTGANTGKLT | 0.87 | | | | | | 1.4 | 1.1 | 1.2 | 2.1 | 2.0 | | | 0.1 | | 0.1 | 91 |
| | AASANSPTYQR | 1.00 | 0.5 | 0.4 | 0.4 | 0.9 | 0.1 | 1.9 | 2.4 | 1.1 | 1.3 | 0.7 | 1.2 | 1.3 | 2.0 | 0.6 | 0.6 | 91 |
| | AASADNNNAPR | 1.00 | 0.1 | 0.1 | 0.1 | 0.2 | 0.5 | 1.7 | 1.9 | 1.1 | 1.2 | 1.6 | | 0.2 | 0.2 | | 0.1 | 90 |

Figure S3. Distribution of top 15 TCRs from each phenotype. The 15 most prevalent TCR α sequences found in the T reg, CD44^{hi}, and CD44^{lo} T cell populations in the data pooled from all four experiments (Table I) are shown in order of decreasing counts within each phenotype. The number of instances is the total count for each TCR in the pooled dataset. Red TCR sequences showed statistically significant differences in their prevalence at different locations based on the generalized linear model testing described in Materials and methods. We considered the Bonferroni adjusted p-value (second column from the left) significant if it was <0.05. Of note, cell purification typically results in the contamination of minor populations (T reg and CD44^{hi} cells) by the major population (naive cells), with the reverse occurring to a much lower degree. A 95–98% purity of the Foxp3⁺ population generally means that 1 out of 20–50 cells are naive cells, which creates a small degree of false overlap. For example, a naive TCR found at 2–5% could be found at 0.1% in the T reg TCR dataset because of impurity from FACS purification.




Figure S4. The CD44^{hi}, CD44^{lo}, and Foxp3⁺ TCR repertoires are distinct. (A) The frequency of the 50 most abundant TCRs in the Foxp3⁺ and CD44^{lo} subsets are shown as in Fig. 2 A. (B) Analysis of mouse-to-mouse variability. Morisita-Horn similarity indices from individual mice datasets (experiment 4 in Fig. S1) show that the various subsets use distinct TCR repertoires (left), consistent with analysis of experiments using pooled mice (Fig. 2 B). However, there was variability between individual mice (right) that was not obvious in those experiments using pooled mice (Fig. 2 B). (C) The three most frequent TCR α sequences from each phenotype were selected, and their frequency within each phenotype in each experiment was plotted. Different symbols represent each of the four experiments. Each TCR tends to be prominent in only one of the three phenotypes, as would be expected from the overall dissimilarity.





Figure S5. The effect of random sampling on observed TCR frequency. Two independent TCR sequence datasets from each of four TRAV14 cDNA libraries were obtained by random sampling, with 150–200 sequences obtained per dataset. Shown for each sample is the frequency with which each unique TCR α CDR3 amino acid sequence was found in the first (blue) and second (red) dataset.

A



B

Number of TCR- α sequences obtained after lymphopenia-induced proliferation and conversion

| Expt. | Phenotype | Spleen | Lymph node | | Total |
|------------|--------------------|--------|------------|-----|-------|
| | | | Mes | Crv | |
| 1, mouse 1 | Foxp3 ⁺ | 159 | 171 | 194 | 524 |
| | Foxp3 ⁻ | 151 | 147 | 172 | 470 |
| 1, mouse 2 | Foxp3 ⁺ | 162 | 150 | 185 | 497 |
| | Foxp3 ⁻ | 184 | 180 | 209 | 573 |
| 1, mouse 3 | Foxp3 ⁺ | 176 | 123 | 175 | 474 |
| | Foxp3 ⁻ | 162 | 170 | 166 | 498 |
| 1, mouse 4 | Foxp3 ⁺ | 184 | 174 | 174 | 532 |
| | Foxp3 ⁻ | 155 | 200 | 174 | 529 |
| 2, mouse 1 | Foxp3 ⁺ | 404 | 413 | 159 | 976 |
| | Foxp3 ⁻ | 201 | 154 | 193 | 548 |
| 2, mouse 1 | Foxp3 ⁺ | 367 | 332 | 215 | 914 |
| | Foxp3 ⁻ | 150 | 248 | 190 | 588 |
| | | | | | 7,123 |

C

TCR- α distribution after lymphopenia-induced proliferation and conversion

| CDR3 a.a. sequence | Precursor | Foxp3 ⁺ | | | | | | | | | | | | Foxp3 ⁻ | | | | | | | | | | | | | | |
|--------------------------------|-----------------|--------------------|------|------|---------|------|------|---------|------|------|---------|------|------|--------------------|------|------|---------|------|------|---------|-----|------|---------|-----|------|-----|-----|-----|
| | | mouse 1 | | | mouse 2 | | | mouse 3 | | | mouse 4 | | | mouse 1 | | | mouse 2 | | | mouse 3 | | | mouse 4 | | | | | |
| | | Spl | Mes | Crv | Spl | Mes | Crv | Spl | Mes | Crv | Spl | Mes | Crv | Spl | Mes | Crv | Spl | Mes | Crv | Spl | Mes | Crv | Spl | Mes | Crv | | | |
| Top 14 Foxp3 ⁺ TCRs | AASANSPTYQR | 1.1 | 7.5 | 12.3 | 5.2 | 46.9 | 13.3 | 8.1 | 2.8 | 2.4 | 0.6 | 9.2 | 6.3 | 2.9 | 2.0 | 0.7 | 0.6 | 2.2 | 0.5 | 0.6 | 3.2 | 0.5 | 1.7 | | | | | |
| | AARNYNQGKLI* | 0.2 | 2.5 | 4.7 | 15.5 | 3.7 | 19.3 | 30.8 | 6.3 | 8.1 | 8.6 | 1.6 | 2.3 | | 0.7 | 0.6 | | 0.5 | | 1.2 | 4.8 | 0.6 | 1.0 | 5.2 | | | | |
| | AARHNTNTGKLT | | | | | | | | | | | 25.5 | 27.0 | 47.1 | | | | | | | | | | | | | | |
| | AASWAQVVGQLT | | | | | 11.1 | 25.3 | 30.3 | | | | | | | | | | | | | | | | | | 2.0 | | |
| | AASASGSFNKLT | | 18.9 | 15.2 | 20.1 | 0.6 | | | | | | | | | | | | | | | | | | | | | | |
| | AASEENYNQGKLI | | | | | | | | | | | 17.9 | 20.1 | 13.8 | | | | 1.6 | | | | | | | | 2.6 | 0.5 | 1.7 |
| | AATGNYKYV | 0.2 | 3.8 | 6.4 | 2.6 | 8.6 | 9.3 | 4.3 | 2.3 | 6.5 | 0.6 | 1.6 | 7.5 | 0.6 | | | | 0.5 | | 0.6 | 0.6 | | | | | | | |
| | AASLSGSFNKLT | 0.2 | | 1.8 | 3.6 | 0.6 | | | 9.1 | 22.8 | 17.7 | | | | | | | 0.5 | | | | 0.6 | | | | | | |
| | AASSAQVVGQLT | | | | | | | | 18.8 | 8.1 | 12.0 | | | | | | | 1.1 | | | | | | | | | | |
| | AASTGTYQR | | | | | | | | | | | 20.7 | 7.5 | 2.3 | | | | | | | | | | | | | | |
| | AASADNAGAKLT | 0.2 | 5.7 | 5.3 | 2.6 | | | | 2.8 | 4.1 | 2.3 | | | | | | | 0.5 | 0.6 | | | | | | | | 2.3 | |
| | AARGTNAYKVI | | | | | | | | 5.7 | 8.1 | 9.7 | | | | | | | | | | | | | | | | | |
| | AASGETGGLSGKLT | | | | | | | | 7.4 | 3.3 | 10.9 | | | | | | | 0.5 | | | 0.6 | 0.6 | 1.2 | | | | | |
| | AASPSGTGSNRLT | | 11.9 | 2.9 | 4.1 | | | | | | | | | | | | | | | | | | | | | | | |
| Top 14 Foxp3 ⁻ TCRs | AASRNSNYQLI | | | | | | | | | | 3.3 | | | 0.7 | 1.4 | 2.9 | 0.5 | 0.5 | 48.8 | 10.0 | 7.8 | 15.5 | 2.0 | 6.3 | | | | |
| | AASRNSYAQGLT | | | | 0.6 | 0.5 | | | | | | | | 0.7 | | | 34.2 | 23.9 | 22.5 | | | | | | | | | |
| | AASDETGNTGKLI | | | | | | | 3.4 | 1.7 | | | | | 0.7 | 15.7 | | 0.5 | 10.5 | | | 3.0 | | | | 5.7 | | | |
| | AASAYRAGNKLT | | | | | | | | | | | | | 10.6 | 0.7 | 25.6 | | | | | | | | | | | | |
| | AATSNNNNAPR | | | | 3.7 | 2.2 | 0.6 | 0.6 | 1.1 | 0.6 | 1.7 | | | | | | 1.1 | 23.9 | | 0.6 | 1.8 | | | | 1.7 | | | |
| | AASGYGSSGNKLI* | 4.5 | 1.3 | | 7.4 | 7.3 | 2.2 | 1.1 | | | | 0.6 | | | 2.0 | 0.7 | 2.3 | 3.3 | 1.7 | 5.7 | 0.6 | 1.2 | 1.9 | 3.5 | 5.2 | | | |
| | AASPRNSGGSNYKLT | | 6.3 | 0.6 | 0.5 | | | 0.6 | | | | | | | 5.3 | 1.4 | 1.7 | 0.5 | | | 8.6 | 2.4 | 4.8 | 1.3 | | | | |
| | AASASGNTGKLI | 0.2 | | 0.6 | | | | | | | | 0.6 | | | 2.0 | 4.1 | | 0.5 | 1.7 | | 1.2 | 1.8 | 5.2 | 7.0 | | | | |
| | AASAGGGNYKPT | | | | | | | | | | | | | | 9.9 | 10.9 | 0.6 | | | | 0.6 | 1.8 | 0.6 | 0.6 | 1.0 | | | |
| | AASARATGGLSGKLT | | | | | | | | | | | | | | 1.3 | 6.8 | 0.6 | | | | 2.5 | 5.3 | | | 6.0 | | | |
| | AASAHHTGGLSGKLT | | | | | | | | | | | | | | | | | | | | 3.7 | 9.4 | | | 0.6 | 7.5 | | |
| | AASASQVVGQLT | | | | 0.6 | 2.0 | | | | | | | | | | | | 0.5 | 17.2 | | | | | | | | | |
| | AGNYGSSGNKLI | 0.7 | | | | | | | | | | | | | 0.7 | | | | | | | | | | 10.3 | 2.0 | 6.3 | |
| | AASGGTGGYKVV | 1.9 | | | | | | | | | | | | | | | | 0.6 | 0.6 | | 0.6 | 9.4 | 3.6 | 1.3 | 1.1 | | | |

Figure S6. Analysis of the immune response caused by Foxp3⁻ cells in lymphopenic hosts. (A) The frequencies of Foxp3⁺ cells arising from the transferred Foxp3⁻ T cells are summarized, with each line representing an independent experiment. The open circles represent the mean values (\pm SEM) from three mice within an independent experiment; the closed circles are values from experiments that consisted of pooled cells. The dashed line is the percentage of Foxp3⁺ cells found in a normal animal (for comparison). (B) Description of TCR sequence datasets obtained 2.5 wk after adoptive transfer of Foxp3⁻ cells into *Tcrb*^{-/-} hosts. The total number of sequences by experiment, location (Crv, cervical; Mes, mesenteric; Spl, spleen) and phenotype are shown. (C) The 14 most prevalent TCR sequences pooled from the four mice in experiment 1 are listed. The 15th most frequent TCR in the Foxp3⁺ and Foxp3⁻ TCRs are each also found in the opposite dataset, as indicated by asterisks. We did not observe a strong skewing of T reg TCR usage based on anatomical location in these mice, unlike normal mice (Fig. 2), possibly as a result of the empty T reg cell niche in lymphopenic animals. Precursor frequency (%) is calculated using 534 TCR α sequences from the sorted CD4⁺Foxp3⁻ input cell population (note that 0.2% represents a TCR found once in this dataset).




Figure S8. Reproducibility of TCR-dependent conversion. Foxp3⁻ CD4⁺ cells were transferred into $\alpha\beta$ T cell-deficient hosts and recovered 2.5 wk later for TCR sequencing (see Fig. 4 and Figs. S4–S6). TCRs that were identified at a frequency of >1% in two or more recipients were selected, and the frequencies of the indicated TCR in each of the six individual mice are shown. The frequencies within the Foxp3⁺ (converted) population (green) are shown above the axis, and the frequencies within the Foxp3⁻ (nonconverted) population (orange) are shown below the axis. Ms, mouse.

| TCR α CDR3 Sequence | Conv % | Post-transfer | | Normal peripheral TCRs | | | Thymic data set | |
|----------------------------|--------|--------------------|--------------------|------------------------|-------------------|--------------------|--------------------|--------------------|
| | | Foxp3 ⁺ | Foxp3 ⁻ | Foxp3 ⁺ | CD44 ^b | CD44 ^{hi} | Foxp3 ⁺ | Foxp3 ⁻ |
| AASDYGSSGNKLI | 100 | 263 | | 50 | 2 | 1 | 4 | 1 |
| AASRPSNNRIF | 100 | 192 | | 2 | | | | |
| AAKNGTGGLSGKLT | 100 | 187 | | | | | | |
| AARTNYAQGLT | 100 | 185 | | | | | | |
| AASASGSFNKLT | 100 | 96 | | 4 | 1 | 1 | | 1 |
| AASTGTYQR | 100 | 55 | | 4 | | | | |
| AASKDNYAQGLT | 100 | 51 | | | | | | |
| AARDYGGSGNKLI | 100 | 43 | | | | | | |
| AARGTNAYKVI | 100 | 37 | | 10 | | | 3 | 5 |
| AASPSGTGSNRLT | 100 | 32 | | | | | | |
| AAPYQGGRALI | 100 | 30 | | | | | | |
| AASDGTYQR | 100 | 21 | | 5 | | | 4 | |
| AASAPSNRIF | 100 | 20 | | 1 | | | | |
| AASGGNYAQGLT | 100 | 127 | | 1 | 4 | 2 | 2 | 1 |
| AAKNGTGGLSDIQN | 100 | 26 | | | | | | |
| AASAGTYQR | 97.6 | 50 | 1 | 16 | | 1 | 3 | 1 |
| AATGNYKYV | 97.3 | 132 | 3 | 3 | 10 | | 1 | 3 |
| AASLSGSFNKLT | 97.2 | 86 | 2 | 12 | 10 | | 1 | 1 |
| AARHNTNTGKLT | 96.6 | 176 | 5 | | | | | |
| AASSAQVVGQLT | 96.3 | 64 | 2 | | | | | |
| AASWAQVVGQLT | 95.8 | 112 | 4 | | | 1 | | |
| AASADAQGLT | 95.8 | 28 | 1 | 2 | 1 | | | |
| AASPAAGTGSNRLT | 95.7 | 27 | 1 | | | | | |
| AASSGTYQR | 95.3 | 25 | 1 | 38 | 2 | 1 | 3 | |
| AASAGNYAQGLT | 95.1 | 47 | 2 | 5 | 8 | | | 4 |
| AASEDAQGLT | 93.9 | 56 | 3 | | 1 | | | |
| AASGSQVVGQLT | 93.3 | 34 | 2 | | | | | |
| AASADNNRIF | 93.1 | 33 | 2 | 29 | 2 | | | |
| AASEYNYGNEKIT | 88.9 | 205 | 21 | | | | | |
| AASDEGNYKYV | 87.6 | 26 | 3 | 1 | 2 | | | |
| AASANSPTYQR | 87.3 | 278 | 33 | 28 | 91 | 74 | 3 | 23 |
| AARNYNQGKLI | 85.5 | 180 | 25 | 61 | 19 | 9 | 19 | 13 |
| AASGETGGLSGKLT | 85.5 | 36 | 5 | 2 | | | | |
| AASADNAGAKLT | 85.4 | 50 | 7 | 21 | 2 | 8 | | 1 |
| AASSNSPTYQR | 85.1 | 21 | 3 | 7 | 8 | 29 | 1 | 4 |
| AASEENYNQGKLI | 68.9 | 92 | 34 | 2 | | | | |
| AAMGNMGYKLT | 66.0 | 19 | 8 | | | 2 | | 1 |
| AANYNQGKLI | 59.2 | 62 | 35 | 7 | 19 | 13 | | 3 |
| AASWGNNKLT | 57.1 | 13 | 8 | | | | | |
| AANSNSAGNKLT | 43.9 | 22 | 23 | | | | | |
| AASGYGSSGNKLI | 32.7 | 32 | 54 | 13 | 142 | 7 | | 2 |
| AASTNTGKLT | 30.6 | 7 | 13 | 4 | 23 | 17 | | |
| AASAGNSNNRIF | 26.2 | 10 | 23 | | | | | |
| AASGAQVVGQLT | 23.2 | 7 | 19 | 13 | | | | 1 |

| TCR α CDR3 Sequence | Conv % | Post-transfer | | Normal peripheral TCRs | | | Thymic data set | |
|----------------------------|--------|--------------------|--------------------|------------------------|-------------------|--------------------|--------------------|--------------------|
| | | Foxp3 ⁺ | Foxp3 ⁻ | Foxp3 ⁺ | CD44 ^b | CD44 ^{hi} | Foxp3 ⁺ | Foxp3 ⁻ |
| AATSNNNNAPR | 20.0 | 18 | 59 | 3 | | 4 | | 1 |
| AASWSNNRLT | 18.5 | 5 | 18 | | 1 | | | |
| AASGNNAGAKLT | 17.6 | 6 | 23 | | 7 | | | 1 |
| AASARNYAQGLT | 16.0 | 10 | 43 | | | | | |
| AAYNNAPR | 14.8 | 7 | 33 | 33 | 1 | 14 | | |
| AASPRNSGGSNYKLT | 14.3 | 13 | 64 | | 3 | 12 | | |
| AASGGNYKPT | 11.4 | 3 | 19 | 1 | 5 | 1 | | 2 |
| AGNYGSSGNKLI | 10.3 | 6 | 43 | 2 | 11 | 2 | | |
| AASEDNNNAPR | 9.6 | 3 | 23 | 7 | 196 | 7 | | 13 |
| AASASQVVGQLT | 9.3 | 4 | 32 | 1 | | | | |
| AASWVVGQLT | 7.2 | 2 | 21 | | | | | |
| AASGSGSWQLI | 6.0 | 11 | 141 | 15 | | 2 | 3 | 3 |
| AASEDETGNTGKLI | 5.9 | 10 | 130 | 11 | 1 | 1 | | |
| AASVNTGKLT | 4.9 | 4 | 63 | 14 | | 39 | 1 | |
| AASQGGSAKLI | 4.6 | 1 | 17 | 6 | 153 | 7 | | 4 |
| AASASGNTGKLI | 3.9 | 2 | 40 | | | | | |
| AASDPGYNKLT | 3.9 | 1 | 20 | | 1 | 6 | | |
| AASENNYAQGLT | 3.9 | 5 | 101 | 4 | 53 | 5 | | 5 |
| AASPTASLGKLT | 3.6 | 1 | 22 | 2 | 22 | 1 | | 4 |
| AASRNSNYQLI | 3.5 | 7 | 159 | 1 | | 2 | | |
| AASGGTGGYKVV | 2.7 | 1 | 29 | 6 | 112 | 28 | | 14 |
| AASRSNYAQGLT | 1.1 | 2 | 154 | 2 | | | | |
| AASAYRAGNKLT | 0.0 | | 61 | | | | | |
| AASAGGGNYKPT | 0.0 | | 41 | | 4 | 19 | | |
| AASVDNYAQGLT | 0.0 | | 40 | | 5 | 6 | | 2 |
| AASARATGGLSGKLT | 0.0 | | 38 | | | | | |
| AASAHHTGGLSGKLT | 0.0 | | 38 | | | | | |
| AANNYAQGLT | 0.0 | | 31 | 2 | | 9 | | |
| AASEGGSNAKLT | 0.0 | | 31 | | | | | |
| AASGPSFSGSWQLI | 0.0 | | 30 | | | | | |
| AASRNTGKLI | 0.0 | | 25 | 1 | 4 | 12 | | 1 |
| AASEPGYNKLT | 0.0 | | 22 | 2 | | 1 | | |
| AASADNYAQGLT | 0.0 | | 21 | 9 | 46 | 14 | 3 | 2 |
| AASTSNNNAPR | 0.0 | | 21 | 2 | | 15 | | |
| AASIDNYAQGLT | 0.0 | | 20 | | 3 | | | |
| AASKNSNYQLI | 0.0 | | 20 | | 3 | 3 | | |
| AAMNQGGSAKLI | 0.0 | | 19 | 2 | 42 | 1 | | 3 |
| AAGDTNAYKVI | 0.0 | | 19 | | 5 | 2 | | 3 |
| AANANNNAGAKLT | 0.0 | | 18 | | | | | |
| AAMRQGGRALI | 0.0 | | 18 | | | | | |
| AASQDQVVGQLT | 0.0 | | 16 | | | | | |
| Sum: | | 3417 | 2126 | 467 | 1025 | 379 | 51 | 123 |
| Total in data set: | | 3917 | 3206 | 5973 | 6003 | 5947 | 955 | 1149 |

Figure S9. Comparison of the normal dataset with TCRs found after adoptive transfer of Foxp3⁻ cells into T cell-deficient hosts. TCRs isolated after adoptive transfer are listed by their ability to facilitate peripheral conversion (Conv %) as in Fig. 4 B. Rare TCRs found at <0.5% in the posttransfer Foxp3⁺ and Foxp3⁻ subsets were excluded. The number of times the TCR was found in the posttransfer and normal peripheral and thymic TCR datasets is shown. These more abundant TCRs found in our peripherally converted dataset (Conv >80%) account for ~5% (302 out of 5,973) of the total sequences in the normal T reg TCR repertoire. However, the appearance of a number of these TCRs in the thymic T reg cell subset suggests that the actual contribution of peripheral conversion may be considerably lower under normal conditions.




Figure S10. Recirculation of peripheral CD4⁺ T cells to the thymus. 20 million CD4⁺ T cell-enriched spleen and lymph node cells were injected into normal congenic recipients. 1 wk later, the spleen and thymus were harvested and analyzed by flow cytometry to determine the percentage of CD4⁺ T cells derived from the donor (left), and the percentage of those that are Foxp3⁺ (right). Data are pooled from two independent experiments ($n = 5$ mice) and are summarized in the bottom graphs (closed circle, individual mouse; horizontal line, mean). To estimate the percentage of thymic T reg cells that come from recirculating peripheral T cells, we assumed that the behavior of our adoptively transferred CD4⁺ cells represented that of the normal peripheral T cell population. Therefore, recirculating cells comprise $\sim 0.8\%$ of the CD4SP population (0.03% of donor T cells in the CD4SP thymus multiplied by 26.3, the ratio of host to donor cells in the spleen [1:0.038]). Because 16.4% of recirculating cells are Foxp3⁺, this suggests that recirculating T reg cells comprise 0.13% of the CD4SP population. Thus, $\sim 4\%$ of the normal thymic T reg cell subset may arise from recirculation (0.13% of $\sim 3\%$, the normal thymic T reg cell frequency; not depicted). If we assume that T reg cells that develop in the periphery recirculate to the thymus with the same frequency as estimated, then the extent of thymic recirculation is not sufficient to account for the presence of thymic T reg cells with TCRs that are also found in the converted population. For example, two of the most frequent TCRs found within the converted Foxp3⁺ population, represented by the CDR3 amino acid sequences AASDYGSSGNKLI and AASANSPTYQR (see Fig. S7), are found in the normal T reg cell population at a frequency of 0.8 and 0.4%, respectively. Therefore, we could expect that they would account for 0.032% (0.8 \times 4%) and 0.016% (0.4 \times 4%) of thymic T reg cells. However, their frequencies within the normal thymic Foxp3⁺ population are far greater (0.4 and 0.3%, respectively).